On Demand ACAAI 2021 Annual Scientific Meeting General Sessions

Cost: $345 for College members, $425 for non-members.

You can earn up to 60 AMA PRA Category 1 Credits™. This collection covers sessions from Friday, Saturday, Sunday, and Monday.

Sessions included:

  • Non-Infectious Complications of Immunodeficiency
  • Physician Health and Wellness in Allergy and Immunology: Challenges and Strategies
  • Owning Anaphylaxis- An Update on Anaphylaxis
  • Regional Dermatitis: How to Make Heads or Tails out of Rashes
  • Allergy and Immunology Issues During Travel
  • The Multidisciplinary Approach to the Management of Chronic Cough
  • Solving The Puzzle of Food Allergy Prevention
  • Supplements and More: Achieving A Global Approach to the Patient Who Wants More than just Traditional Therapies.
  • Presidential Plenary: Innovate, Diversify and Expand Allergy/Immunology Practice
  • Addressing Mental Health Challenges in Patients with Asthma and Allergic Diseases
  • Combatting Misinformation in Medicine
  • Don’t Sleep on Sleep – Why Sleep Disorders are Important to the Allergist
  • Drug Hypersensitivity Reactions in 2021: What Should We Know
  • Management of Nasal Polyps: When Are Surgery And Biologic Agents Required?
  • 7 for 11, Update on Pediatric Allergy & immunology - Cosponsored with AAP-Section of Allergy & Immunology
  • Editor’s Pick – Best Articles from Annals of Allergy, Asthma and Immunology
  • Emerging Concepts in Environmental Immunotherapy
  • Coding and Government Relations
  • Disparities in the Air We Breathe
  • Practical Management of AERD
  • Role of Genetic Testing in Diagnosis and Management of Immunodeficiency
  • Plenary - Innovating Our Way Out of the Pandemic: Vaccines and Therapeutics
  • Updated Diagnostics: CRD, BAT, and Emerging Diagnostic Testing
  • Where Are We With Biologic Therapies for Asthma?
  • What’s That Rash? Doctor, What’s Wrong With My Skin? – JEOPARDY!
  • Building ABAI Continuing Certification Together
  • EAACI - New Avenues for Allergy and Asthma Prevention
  • ICS/Formoteral or SABA Alone?
  • Plenary - Implementing New Guidelines Into Practice
  • 7 for 11: Hot Topics in Dermatology
  • Allergen Mixing in the Allergist’s Office - The Changing Environment in Allergy and Immunology Extract Mixing
  • The Growing Epidemic of Secondary Immunodeficiency
  • Addressing Non-IgE Mediated Food Allergy
  • Allergen Mixing in the Allergist’s Office - The Compliant Mixing Room
  • Starting an OIT Program in Private Practice from the Ground Up

Release Date: 11/22/2021
Expiration Date: 11/21/2024

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 60 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract.
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders.
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 60.00 AMA PRA Category 1 Credit™
  • 60.00 Attendance
Course opens: 
Course expires: 

Available Credit

  • 60.00 AMA PRA Category 1 Credit™
  • 60.00 Attendance
Please login or create an account to take this course.
Please login or create an account to take this course.
Please login or create an account to take this course.
Please login or create an account to take this course.


Please login or create an account to take this course.